Company intelligence / Profile preview

Lusaris Therapeutics

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Lead program LSR-1019, a proprietary sublingual orally disintegrating tablet formulation of 5-MeO-DMT targeting treatment-resistant depression, was preparing to enter Phase 1 with topline data expected mid-2023, but publicly available sources list the program as preclinical and the company as out of business, with no reported clinical efficacy results yet.[1][4][6][9]

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

LSR-1019

Unknown

Partnerships

Catalent (exclusive worldwide license to Zydis fast-dissolving tablet technology for all 5-MeO-DMT applications)[1][4]

Beyond the preview

Go deeper on Lusaris Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lusaris Therapeutics.

Explore the full profile